Extended Platelet Parameters as a Means to Differentiate Immune Thrombocytopenia From Hypo-proliferative Thrombocytopenias.
Completed
Conditions studied: Immune Thrombocytopenia, Chemotherapy Induced Thrombocytopenia, Myelodysplasia, Aplastic Anaemia
In brief
To utilise extended platelet parameters in order to individuate Immune Thrombocytopenia (ITP) from hypo-proliferative causes of thrombocytopenia. To develop the clinical potential of the extended platelet parameters as they pertain to distinguishing different causes of thrombocytopenia from one another. To test the hypothesis that mean platelet component (MPC) and mean platelet mass (MPM) might distinguish between thrombocytopenia related to bone marrow dysfunction and immune mediated destruction of platelets.
Key facts
- Study ID
- NCT01933035
- Run by
- Beth Israel Medical Center
- People needed
- 50
- Starts
- 2013-10-01
- Expected to finish
- 2015-10-01
- Last updated by the study team
- 2016-05-17
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- All individuals age 18yrs and above capable of rendering consent
- Known ITP confirmed by response to intravenous immune globulin (IVIG), glucocorticoids, or winRho and exclusion of all other possible causes of thrombocytopenia
- Confirmed aplastic anemia [as assessed through bone marrow trephine biopsy]
- Chemotherapy induced thrombocytopenia assessed at time of predicted nadir.
You may not qualify if…
- Suspected multifactorial thrombocytopenias and thrombocytopenia due to hypersplenism
- Chronic active hepatitis
- Those infected with HIV
- Patients receiving concomitant radiotherapy
- Gravid females
- Congenital thrombocytopenias
Where it is running
- Roosevelt Hospital — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.